0Y3M Stock Overview
A late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Prothena Corporation plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.07 |
| 52 Week High | US$25.67 |
| 52 Week Low | US$7.07 |
| Beta | 0.10 |
| 1 Month Change | -34.52% |
| 3 Month Change | -48.98% |
| 1 Year Change | -67.86% |
| 3 Year Change | -80.24% |
| 5 Year Change | n/a |
| Change since IPO | -83.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0Y3M | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -19.2% | 1.4% | 0.4% |
| 1Y | -67.9% | -13.4% | -0.4% |
Return vs Industry: 0Y3M underperformed the UK Biotechs industry which returned -15.3% over the past year.
Return vs Market: 0Y3M underperformed the UK Market which returned 0.3% over the past year.
Price Volatility
| 0Y3M volatility | |
|---|---|
| 0Y3M Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 10.9% |
| 10% least volatile stocks in GB Market | 3.1% |
Stable Share Price: 0Y3M's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0Y3M's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 163 | Gene Kinney | www.prothena.com |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer’s disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer’s disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer’s disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases.
Prothena Corporation plc Fundamentals Summary
| 0Y3M fundamental statistics | |
|---|---|
| Market cap | US$392.40m |
| Earnings (TTM) | -US$122.31m |
| Revenue (TTM) | US$135.16m |
2.8x
P/S Ratio-3.1x
P/E RatioIs 0Y3M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0Y3M income statement (TTM) | |
|---|---|
| Revenue | US$135.16m |
| Cost of Revenue | US$222.52m |
| Gross Profit | -US$87.36m |
| Other Expenses | US$34.95m |
| Earnings | -US$122.31m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.27 |
| Gross Margin | -64.64% |
| Net Profit Margin | -90.49% |
| Debt/Equity Ratio | 0% |
How did 0Y3M perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 06:08 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Prothena Corporation plc is covered by 24 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Geoffrey Meacham | Barclays |
| Tazeen Ahmad | BofA Global Research |
| null null | BTIG |